MOF-Based Polymeric Nanocomposite Films as Potential Materials for Drug Delivery Devices in Ocular Therapeutics

Please use this identifier to cite or link to this item:
Información del item - Informació de l'item - Item information
Title: MOF-Based Polymeric Nanocomposite Films as Potential Materials for Drug Delivery Devices in Ocular Therapeutics
Authors: Gandara-Loe, Jesús | Souza, Barbara E. | Missyul, Alexander | Giraldo, German | Tan, Jin-Chong | Silvestre-Albero, Joaquín
Research Group/s: Materiales Avanzados
Center, Department or Service: Universidad de Alicante. Departamento de Química Inorgánica | Universidad de Alicante. Instituto Universitario de Materiales
Keywords: Brimonidine | MOFs | Polyurethane | Ocular plugs | Drug delivery
Knowledge Area: Química Inorgánica
Issue Date: 12-Jun-2020
Publisher: American Chemical Society
Citation: ACS Applied Materials & Interfaces. 2020, 12(27): 30189-30197.
Abstract: Novel MOF-based polymer nanocomposite films were successfully prepared using Zr-based UiO-67 as a metal–organic framework (MOF) and polyurethane (PU) as a polymeric matrix. Synchrotron X-ray powder diffraction (SXRPD) analysis confirms the improved stability of the UiO-67 embedded nanocrystals, and scanning electron microscopy images confirm their homogeneous distribution (average crystal size ∼100–200 nm) within the 50 μm thick film. Accessibility to the inner porous structure of the embedded MOFs was completely suppressed for N2 at cryogenic temperatures. However, ethylene adsorption measurements at 25 °C confirm that at least 45% of the MOF crystals are fully accessible for gas-phase adsorption of nonpolar molecules. Although this partial blockage limits the adsorption performance of the embedded MOFs for ocular drugs (e.g., brimonidine tartrate) compared to the pure MOF, an almost 60-fold improvement in the adsorption capacity was observed for the PU matrix after incorporation of the UiO-67 nanocrystals. The UiO-67@PU nanocomposite exhibits a prolonged release of brimonidine (up to 14 days were quantified). Finally, the combined use of SXRPD, thermogravimetric analysis (TGA), and Fourier transform infrared (FTIR) analyses confirmed the presence of the drug in the nanocomposite film, the stability of the MOF framework and the drug upon loading, and the presence of brimonidine in an amorphous phase once adsorbed. These results open the gate toward the application of these polymeric nanocomposite films for drug delivery in ocular therapeutics, either as a component of a contact lens, in the composition of lacrimal stoppers (e.g., punctal plugs), or in subtenon inserts.
Sponsor: The authors would like to acknowledge financial support from MINECO (MAT2016-80285-p), Spanish ALBA Synchrotron (Project 2020014008), and H2020 (MSCA-RISE-2016/NanoMed Project). B.E.S. thanks the Minas Gerais Research Foundation (FAPEMIG CNPJ n21.949.888/0001-83) for a DPhil scholarship award. J.-C.T. thanks the EPSRC (Grant No. EP/N014960/1) and ERC Consolidator Grant (PROMOFS under the grant agreement 771575) for funding.
ISSN: 1944-8244 (Print) | 1944-8252 (Online)
DOI: 10.1021/acsami.0c07517
Language: eng
Type: info:eu-repo/semantics/article
Rights: © 2020 American Chemical Society
Peer Review: si
Publisher version:
Appears in Collections:INV - LMA - Artículos de Revistas

Files in This Item:
Files in This Item:
File Description SizeFormat 
ThumbnailGandara-Loe_etal_2020_ACSApplMaterInterfaces_final.pdfVersión final (acceso restringido)2,11 MBAdobe PDFOpen    Request a copy
ThumbnailGandara-Loe_etal_2020_ACSApplMaterInterfaces_accepted.pdfAccepted Manuscript (acceso abierto)719,33 kBAdobe PDFOpen Preview

Items in RUA are protected by copyright, with all rights reserved, unless otherwise indicated.